Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.
Mateo Sanchis-BorjaFlorian GuisierAurélie SwalduzHubert CurcioVictor BasseChristophe MaritazChristos ChouaidJean-Bernard AuliacPublished in: OncoTargets and therapy (2024)
mutation-positive NSCLC following emergence of the osimertinib resistance mutations, L718Q or G724S. Afatinib appears to be a promising treatment option in this setting.